|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Hospital Principe de Asturias |
|---|---|
| Collaborator: |
Pfizer |
| Information provided by: | Hospital Principe de Asturias |
| ClinicalTrials.gov Identifier: | NCT00127985 |
Purpose
Background: Systemic corticosteroids are considered in patients with an adverse clinical course suffering from conditions like the acute respiratory distress syndrome (ARDS) and septic shock. Treated patients not only show improved respiratory function, but also hemodynamic status and overall multiple organ dysfunction score.
Objective: To evaluate the safety and effectiveness of 6-methyl-prednisolone on the clinical course of multiple organ dysfunction syndrome (MODS).
Design: Multi-center, double-blind, randomized, placebo-controlled.
Intervention: Intravenous administration of 6-methyl-prednisolone or placebo (aqueous solution). The duration of the study medication administration protocol is 32 days (1).
Primary Endpoints:
| Condition | Intervention | Phase |
|---|---|---|
|
Multiple Organ Dysfunction Syndrome |
Drug: 6-methyl-prednisolone |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome |
| Estimated Enrollment: | 240 |
| Study Start Date: | August 2005 |
| Estimated Study Completion Date: | July 2008 |
| Estimated Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active: Experimental
IV 6-methyl-prednisolone
|
Drug: 6-methyl-prednisolone
iv, 2 mg/kg/day, qid
|
|
Comparator: Placebo Comparator
IV Placebo
|
Drug: 6-methyl-prednisolone
iv, 2 mg/kg/day, qid
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Main Inclusion Criteria:
Patients with established, unresolving, refractory MODS, in whom all reversible and treatable causes of persistent MODS have been treated or ruled out:
Additional Inclusion Criteria:
Infections:
Exclusion Criteria:
Immune status and steroid therapy.
Steroid therapy
Other significant pre-existing underlying chronic diseases:
Contacts and Locations| Contact: Miguel Sanchez, MD, PhD | 34-91-887-8100 ext 2205 | miguelsanchez.areachip@wanadoo.es |
| Spain | |
| Hospital Clinic | Recruiting |
| Barcelona, Spain | |
| Contact: Antoni Torres, MD, PhD | |
| Principal Investigator: Antoni Torres, MD, PhD. | |
| Sub-Investigator: Juan Ramón Badía, MD, PhD | |
| Hospital Universitario de la Princesa | Recruiting |
| Madrid, Spain, 28006 | |
| Contact: Antonio Reyes, MD., PhD. 34-91-520-2200 Areyes.hlpr@salud.madrid.org | |
| Contact: Fernando Lopez, MD., PhD. 34-91-520-2200 fld@inicia.es | |
| Principal Investigator: Antonio Reyes, MD., PhD. | |
| Sub-Investigator: Fernando - Lopez, MD, PhD | |
| Francisco Ortuño Anderiz | Recruiting |
| Madrid, Spain, 28040 | |
| Contact: Francisco - Ortuño Anderiz, MD 34-91-330-3223 portunoa@yahoo.es | |
| Sub-Investigator: Fernando - Martinez Sagasti, MD, PhD | |
| Clinica Moncloa | Recruiting |
| Madrid, Spain | |
| Contact: Manuel Alvarez, MD, PhD. | |
| Contact: Juan Jose Oñoro, MD | |
| Principal Investigator: Manuel Alvarez, MD, PhD | |
| María Mar Cruz Acuaroni | Recruiting |
| Toledo, Spain, 45004 | |
| Contact: Maria Mar - Cruz Acuaroni, MD 34-925-26-9237 mdelca@sescam.jccm.es | |
| Contact: Maria José - Pérez Pedrero, MD 34-925-26-9237 | |
| Principal Investigator: Maria Mar - Cruz Acuaroni, MD | |
| Sub-Investigator: Maria Jose - Perez Pedrero, MD | |
| Spain, Madrid | |
| Hospital Principe de Asturias | Recruiting |
| Alcala de Henares, Madrid, Spain, 28805 | |
| Contact: Raul De Pablo 34-91-8871-8100 ext 2205 rdepablosanchez@yahoo.es | |
| Principal Investigator: Raul De Pablo, MD | |
| Study Chair: | Miguel Sanchez, MD, PhD | Hosp. Univ. Principe de Asturias |
More Information
| Responsible Party: | Hospital Principe de Asturias ( Miguel Sanchez Garcia, MD, PhD ) |
| Study ID Numbers: | NAIF6MPMODS088UNK9071296 |
| Study First Received: | August 8, 2005 |
| Last Updated: | May 12, 2008 |
| ClinicalTrials.gov Identifier: | NCT00127985 History of Changes |
| Health Authority: | Spain: Ministry of Health |
|
multiple organ dysfunction syndrome corticosteroids mortality |
|
Anti-Inflammatory Agents Methylprednisolone Antineoplastic Agents Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Antiemetics Prednisolone acetate Hormones Neuroprotective Agents Pathologic Processes Therapeutic Uses Syndrome Multiple Organ Failure |
Methylprednisolone Hemisuccinate Disease Antineoplastic Agents, Hormonal Gastrointestinal Agents Methylprednisolone acetate Protective Agents Glucocorticoids Pharmacologic Actions Shock Autonomic Agents Prednisolone Peripheral Nervous System Agents Central Nervous System Agents |